Clinical Data to Submit Vilazodone NDA without PGx Marker; Reports 11 Percent Revenue Growth in Q3

Clinical Data is planning to submit a new drug application to the US Food and Drug Administration for its investigational depression drug vilazodone in the current quarter. However, due to unfavorable Phase III results on a response biomarker, the company will not be submitting its NDA with a companion test.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories